The use of PDE5 inhibitors in the treatment of benign prostate hyperplasia and lower urinary tract symptoms: preclinical evidences
Abstract
Material-methods The mRNA expression of PDE5 was determined in rat tissues of the lower urinary tract. To test the functional relevance of the PDE5 expression, sildenafil, vardenafil, and tadalafil were tested on pre-contracted isolated rat bladder, prostate and urethra strips. The in vivo efficacy was tested in a partial bladder outlet obstruction (BOO) model after acute and chronic treatment.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.